Altra Bio and Tercen announce new collaboration.

Altra Bio and Tercen announce Partnership.

YON, France May. 9th, 2023 – AltraBio and Tercen announce their partnership to develop automated gating in clinical studies.

Altra Bio’s machine-learning based gating (CytAutomaton) is now available on Tercens flexible visualisation platform.

AltraBio SAS, a leading company in data-analysis and development of automated gating tools, and Tercen Data Analytics Ltd, a leading provider of cytometry cloud-based data analysis software, today announced the integration of CytAutomaton, the Gating Automation tool developed by AltraBio in the Biomedical Data Analysis Platform developed by Tercen to facilitate access and use of this Machine-Learning based approach as well as interaction with generated gating results.

The availability of CytAutomaton in the Tercen platform will allow the users to automatically quantify the cellular populations defined in their gating strategy on all cytometry files and then interact with the results.

For several years, due to the development of new technologies, cytometry data has become more complex, and the volume of data generated continues to increase. Historical manual gating, one of the primary sources of variability for flow cytometry analysis, is no longer suitable for analyzing the large amount of data generated in clinical studies.

The machine-learning based approach developed by AltraBio can fill this gap with a highly proven ability to apply given gating strategies to a large amount of clinical data. This increases the robustness of the gating step, speeds up the process, and saves experts time. Due to the expense of clinical trials, extracting the maximum information is critical. Users now have access to a combination of gating techniques. Supervised gating for the target populations and unsupervised for subpopulations within those target groups.

With this partnership, CytAutomaton runs in the customer’s IT infrastructure due to Tercen’s cloud-native technology. Interactive visualizations and statistics are provided on AltraBios powerful gating models. Both partners are pleased to announce this collaboration which will provide access to quality tools that help clinicians and researchers to use cytometry in high-dimension studies, to speed-up the data processing step, and to increase the robustness of their results.

 

“This partnership is a tremendous opportunity for users to combine the flexibility of the integrative platform provided by Tercen with the huge performances of CytAutomaton.”

Laurent Buffat, CEO of AltraBio.

 

“For the first time, the flow cytometry community now has a single data analysis solution that covers research, preclinical, and clinical studies. We are very excited to be working with AltraBio.”

Faris Naji, CEO of Tercen.